CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
P/B ratio for CSL Limited (CSL.AX)
P/B ratio as of 2024: 5.44
According to CSL Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.44. At the end of 2023 the company had a P/B ratio of 3.75.
P/B ratio history for CSL Limited from 1993 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 5.44 |
| 2023 | 3.75 |
| 2022 | 4.11 |
| 2021 | 11.60 |
| 2020 | 13.69 |
| 2019 | 13.06 |
| 2018 | 15.87 |
| 2017 | 15.29 |
| 2016 | 15.01 |
| 2015 | 15.04 |
| 2014 | 10.22 |
| 2013 | 10.05 |
| 2012 | 5.91 |
| 2011 | 4.60 |
| 2010 | 5.14 |
| 2009 | 4.38 |
| 2008 | 7.30 |
| 2007 | 8.35 |
| 2006 | 6.67 |
| 2005 | 4.21 |
| 2004 | 2.72 |
| 2003 | 2.22 |
| 2002 | 6.85 |
| 2001 | 15.89 |
| 2000 | 9.25 |
| 1999 | 6.21 |
| 1998 | 5.68 |
| 1997 | 3.89 |
| 1996 | 2.60 |
| 1995 | 1.64 |
| 1994 | 1.06 |
| 1993 | 1.86 |